Ovid Therapeutics Inc represents strong values and a focused corporate philosophy in the field of biopharmaceuticals. The company is dedicated to enhancing the lives of patients and their families by developing innovative therapies for rare neurological disorders. With a commitment to scientific excellence, Ovid Therapeutics is driven by a patient-centric approach, prioritizing their needs and providing potential life-changing solutions. Through strategic partnerships, cutting-edge research, and a deep understanding of the neurological space, Ovid Therapeutics aims to revolutionize the way rare diseases are treated. Their unwavering dedication to making a positive impact makes Ovid Therapeutics Inc a leading force in the biopharmaceutical industry.

Ovid Therapeutics Inc is primarily present in the United States.

Ovid Therapeutics Inc has achieved several significant milestones in its growth and development. The company has successfully initiated Phase 2 clinical trials for its lead product candidate OV101, designed for the treatment of Angelman syndrome and Fragile X syndrome. Ovid Therapeutics Inc has also collaborated with global pharmaceutical companies to advance its research and development efforts. In addition, the company has expanded its pipeline by initiating clinical trials for additional indications. Furthermore, Ovid Therapeutics Inc has successfully raised funding through various financing activities to support its research and development activities. These achievements signify the company's dedication to advancing therapeutic options for patients in need.

Ovid Therapeutics Inc is a biopharmaceutical company specializing in the development of therapies for rare neurological disorders. Founded in 2014, Ovid Therapeutics is focused on delivering innovative treatments for patients with conditions such as Angelman syndrome and Fragile X syndrome. The company's research is centered on understanding the underlying causes of these disorders and developing targeted therapies to address them. Ovid Therapeutics is committed to making significant advancements in the field of neurology and improving the lives of patients with rare neurological conditions through its dedication to scientific excellence and collaboration with healthcare professionals.

The main competitors of Ovid Therapeutics Inc in the market include Sage Therapeutics, Zogenix Inc, and GW Pharmaceuticals.

Ovid Therapeutics Inc is primarily active in the biotechnology industry.

The business model of Ovid Therapeutics Inc. is focused on developing and commercializing novel therapeutics for patients with rare neurological disorders. They aim to identify and develop potential treatments that address the underlying disease biology and provide meaningful clinical benefits. Ovid Therapeutics Inc. strives to leverage scientific and clinical expertise to advance their pipeline of investigational therapies, collaborating with key partners to drive innovation in the field of rare diseases. Their commitment to patients and their families drives their efforts to bring forth innovative solutions and improve the lives of those affected by rare neurological disorders.

P/E odnos Ovid Therapeutics iznosi -2,26.

KUV kompanije Ovid Therapeutics iznosi 149,54.

AlleAktien kvalitativni skor za Ovid Therapeutics je 2/10.

očekivana Ovid Therapeutics promet je 475.962,58 USD.

Dobit očekivana Ovid Therapeutics je -31,51 mil. USD.

Ovid Therapeutics Inc is a biotechnology company focused on developing medications for rare neurological disorders. The company works closely with leading research institutions and pharmaceutical partners to develop a wide range of therapeutics tailored to the individual needs of patients. Ovid Therapeutics' business activities center around three pillars: research and development, partnerships, and commercial activities. The company takes an innovative approach in the field of neuroscience, working on the discovery and development of medications for rare neurological disorders using specialized molecular technologies and knowledge of disease pathophysiology. The main product of Ovid Therapeutics is the investigational drug OV101. This medication is being developed for the treatment of Angelman syndrome (AS) and is currently in Phase 3 of clinical development. OV101 is a highly selective inhibitor of the enzyme GABA-transaminase and aims to maintain GABA signaling, which is crucial for maintaining normal brain function. In addition to OV101, Ovid Therapeutics also has other medications in development, such as the investigational drug OV935 for rare forms of epilepsy and for Angelman syndrome patients with sleep disorders. OV935 is a selective inhibitor of the enzymes TDO and IDO and aims to inhibit the formation of kynurenine signaling, which is responsible for neurological disorders. To further advance these innovative therapeutic approaches in clinical trials, Ovid Therapeutics has formed partnerships with leading research institutions such as Columbia University and the University of Oxford. Additionally, the company collaborates with other biotechnology and pharmaceutical companies to support the research and development of its medications. To promote the introduction and commercialization of its medications, Ovid Therapeutics also has a commercial division. In this department, the company develops marketing strategies and distribution models to successfully position its products in the market. Overall, Ovid Therapeutics focuses on the discovery, development, and commercialization of groundbreaking therapeutics for rare neurological disorders. The close collaboration with leading research institutions and pharmaceutical partners has allowed the company to develop innovative medications aimed at meeting the individual needs of patients. With its various divisions and innovative approach, Ovid Therapeutics has become a pioneering company in the field of neuroscience.

Ovid Therapeutics isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Ovid Therapeutics trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Ovid Therapeutics je US6904691010.

WKN od Ovid Therapeutics je A2DQ8S.

Oznaka za praćenje akcija kompanije Ovid Therapeutics je OVID.

U poslednjih 12 meseci, Ovid Therapeutics je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Ovid Therapeutics će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Ovid Therapeutics trenutno iznosi .

Ovid Therapeutics isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Ovid Therapeutics je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Ovid Therapeutics se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Ovid Therapeutics od 19. 11. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 19. 11. 2024..

Isplata poslednje dividende izvršena je 19. 11. 2024..

U godini 2023 kompanija Ovid Therapeutics je isplatila 0 USD kao dividende.

Dividende od Ovid Therapeutics se isplaćuju u USD.